Literature DB >> 3980651

Antitumour imidazotetrazines. VII. Quantitative analysis of mitozolomide in biological fluids by high-performance liquid chromatography.

J A Slack, C Goddard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3980651

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  8 in total

1.  Relationship between the pharmacokinetics and toxicity of mitozolomide.

Authors:  D J Kerr; J A Slack; P Secrett; M F Stevens; G R Blackledge; C Bradley; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.

Authors:  L L Tsang; P B Farmer; A Gescher; J A Slack
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

Authors:  C Dive; P Workman; J V Watson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma.

Authors:  M Broggini; E Erba; L Morasca; C Horgan; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.

Authors:  C J Brindley; R B Pedley; P Antoniw; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.

Authors:  M McKeage; P Dady; M Clear; A MacDonald
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.

Authors:  C Goddard; J A Slack; M F Stevens
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

8.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Authors:  E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.